JP2012533595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012533595A5 JP2012533595A5 JP2012521008A JP2012521008A JP2012533595A5 JP 2012533595 A5 JP2012533595 A5 JP 2012533595A5 JP 2012521008 A JP2012521008 A JP 2012521008A JP 2012521008 A JP2012521008 A JP 2012521008A JP 2012533595 A5 JP2012533595 A5 JP 2012533595A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- beta
- adrenergic receptor
- receptor agonist
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000000048 adrenergic agonist Substances 0.000 claims 7
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 7
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims 7
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 3
- 238000004090 dissolution Methods 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 235000012054 meals Nutrition 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 229960005105 terbutaline sulfate Drugs 0.000 claims 2
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical group [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 claims 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000000422 nocturnal effect Effects 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 229960000195 terbutaline Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0912646.7A GB0912646D0 (en) | 2009-07-21 | 2009-07-21 | Improvements in or relating to organic compounds |
| GB0912646.7 | 2009-07-21 | ||
| PCT/EP2010/060326 WO2011009818A1 (en) | 2009-07-21 | 2010-07-16 | Beta 2 adrenergic receptor agonists such as terbutaline for use in the treatment of nocturnal hypoglycemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012533595A JP2012533595A (ja) | 2012-12-27 |
| JP2012533595A5 true JP2012533595A5 (enExample) | 2013-09-05 |
| JP6021641B2 JP6021641B2 (ja) | 2016-11-09 |
Family
ID=41058278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012521008A Expired - Fee Related JP6021641B2 (ja) | 2009-07-21 | 2010-07-16 | 夜間低血糖症の治療にて用いるためのテルブタリンなどのベータ２アドレナリン作動性受容体アゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8697755B2 (enExample) |
| EP (1) | EP2456430B1 (enExample) |
| JP (1) | JP6021641B2 (enExample) |
| ES (1) | ES2616322T3 (enExample) |
| GB (1) | GB0912646D0 (enExample) |
| WO (1) | WO2011009818A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| EP2825159B1 (en) | 2012-03-15 | 2022-06-22 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| GB201218012D0 (en) * | 2012-10-08 | 2012-11-21 | Jagotec Ag | Dosage forms |
| EP3865120B1 (en) | 2013-07-19 | 2025-06-25 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| WO2015082389A1 (en) | 2013-12-04 | 2015-06-11 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19809719A1 (de) * | 1998-03-06 | 1999-09-09 | Roehm Gmbh | Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen |
| EP2319585A1 (en) * | 2002-08-29 | 2011-05-11 | Cipla Ltd. | Pharmaceutical products and compositions comprising salmeterol, fluticasone and ipratropium or tiotropium |
-
2009
- 2009-07-21 GB GBGB0912646.7A patent/GB0912646D0/en not_active Ceased
-
2010
- 2010-07-16 US US13/384,388 patent/US8697755B2/en active Active
- 2010-07-16 ES ES10731762.0T patent/ES2616322T3/es active Active
- 2010-07-16 JP JP2012521008A patent/JP6021641B2/ja not_active Expired - Fee Related
- 2010-07-16 EP EP10731762.0A patent/EP2456430B1/en not_active Not-in-force
- 2010-07-16 WO PCT/EP2010/060326 patent/WO2011009818A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012533595A5 (enExample) | ||
| US11000507B2 (en) | Secnidazole for use in the treatment of bacterial vaginosis | |
| RU2012118668A (ru) | Комбинированная терапия с использованием агониста бета 3 адренергического рецептора и антимускаринового средства | |
| WO2011160136A3 (en) | Progesterone containing oral dosage forms and related methods | |
| JP2013529665A5 (enExample) | ||
| RU2011110765A (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
| JP2019502741A5 (enExample) | ||
| JP2013528654A (ja) | インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用 | |
| WO2008122190A1 (en) | The composition comprising l-carnitine or derivatives thereof and its use | |
| AR084093A1 (es) | Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica | |
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| KR102055859B1 (ko) | 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 | |
| JP2007529564A5 (enExample) | ||
| RU2018104691A (ru) | Композиции с модифицированным высвобождением ницерголина | |
| JP2019535830A5 (enExample) | ||
| TWI482632B (zh) | 醫藥用載體及使用該載體的藥物結構 | |
| JP2009522294A5 (enExample) | ||
| CN101040850A (zh) | 秋水仙碱缓释微丸及制备方法 | |
| CN103550182B (zh) | 一种肠溶缓释组合物 | |
| RU2015140567A (ru) | Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами | |
| JP2009507850A5 (enExample) | ||
| RU2015140501A (ru) | Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами | |
| RU2012143550A (ru) | Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для введения вскоре после прекращения введения амиодарона | |
| KR20150063040A (ko) | 간 질환의 치료에 사용하기 위한 메타독신 및 메타독신 연장 방출성 제제 | |
| CN103638085A (zh) | 一种舒胸脉冲控释滴丸及其制备方法 |